Arch Therapeutics Inc (ARTH) Receives $2.83 Average PT from Analysts
Arch Therapeutics Inc (OTCMKTS:ARTH) has been assigned an average rating of “Buy” from the six research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $2.83.
ARTH has been the subject of several analyst reports. ValuEngine downgraded Arch Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, October 12th. Zacks Investment Research upgraded Arch Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 target price for the company in a research note on Tuesday, October 17th. Finally, HC Wainwright set a $3.00 price target on Arch Therapeutics and gave the company a “buy” rating in a report on Tuesday, December 19th.
Shares of Arch Therapeutics (ARTH) traded up $0.05 during midday trading on Friday, reaching $0.51. The company’s stock had a trading volume of 630,723 shares, compared to its average volume of 631,272. Arch Therapeutics has a fifty-two week low of $0.25 and a fifty-two week high of $0.89. The company has a market cap of $78.51, a P/E ratio of -10.20 and a beta of 4.55.
About Arch Therapeutics
Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.
Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.